Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

1.380 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 233
Open 1.380
Bid (Size) 1.350 (200)
Ask (Size) 1.480 (600)
Prev. Close 1.380
Today's Range 1.380 - 1.380
52wk Range 0.4040 - 2.270
Shares Outstanding 40,869,135
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Wider-Than-Expected Q3 2025 Loss Amid Promising Clinical Data ↗
ALX Oncology reports a wider Q3 2025 loss but reveals strong clinical data for its cancer drug evorpacept, extending its cash runway into 2027. 
Via Chartmill
News headline image
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From ALX Oncology
Via GlobeNewswire

Performance

YTD
-11.5%
-11.5%
1 Month
-8.0%
-8.0%
3 Month
+42.1%
+42.1%
6 Month
+220.0%
+220.0%
1 Year
+13.1%
+13.1%

More News

Read More
News headline image
Examining the Future: ALX Oncology Holdings's Earnings Outlook ↗
Via Benzinga
News headline image
ALX Oncology to Report Third Quarter 2025 Financial Results and Pipeline Progress Including Evorpacept CD47 Biomarker Data to be Presented at Upcoming SITC Annual Meeting
From ALX Oncology
Via GlobeNewswire
News headline image
Earnings Scheduled For November 7, 2025 ↗
Via Benzinga
News headline image
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
From ALX Oncology
Via GlobeNewswire
News headline image
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From ALX Oncology
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Via Benzinga
News headline image
Which stocks are gapping on Friday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
From ALX Oncology
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
ALX Oncology to Participate in Upcoming Investor Conferences in September
From ALX Oncology
Via GlobeNewswire
News headline image
Unusual volume stocks in Friday's session ↗
Via Chartmill
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket ↗
Via Benzinga
News headline image
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
From ALX Oncology
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
Via Chartmill
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Q2 2025 Results with Wider Loss but Strong Clinical Progress ↗
Via Chartmill

Frequently Asked Questions

Is ALX Oncology Holdings Inc. - Common Stock publicly traded?
Yes, ALX Oncology Holdings Inc. - Common Stock is publicly traded.
What exchange does ALX Oncology Holdings Inc. - Common Stock trade on?
ALX Oncology Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ALX Oncology Holdings Inc. - Common Stock?
The ticker symbol for ALX Oncology Holdings Inc. - Common Stock is ALXO on the Nasdaq Stock Market
What is the current price of ALX Oncology Holdings Inc. - Common Stock?
The current price of ALX Oncology Holdings Inc. - Common Stock is 1.380
When was ALX Oncology Holdings Inc. - Common Stock last traded?
The last trade of ALX Oncology Holdings Inc. - Common Stock was at 11/14/25 04:00 PM ET
What is the market capitalization of ALX Oncology Holdings Inc. - Common Stock?
The market capitalization of ALX Oncology Holdings Inc. - Common Stock is 56.40M
How many shares of ALX Oncology Holdings Inc. - Common Stock are outstanding?
ALX Oncology Holdings Inc. - Common Stock has 56M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.